Portfolio News

Hongene Biotech Announces Grant to Expand Global Access to mRNA Vaccine Raw Materials

Simcere Zaiming's a Bispecific ADC SIM0610 Doses First Patient in a Phase I Clinical Trial

Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

Simcere Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

Envafolimab Submits New Drug Application for Advanced Biliary Tract Cancer, Accepted for Review by NMPA

MicroPort NeuroScientific’s StraitPass™ Neuroendoscope Enters China’s “Green Channel” for Innovative Medical Devices

Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

Phase III clinical trial (SCORES) data of Suvemcitug published in Nature Cancer

TASTE-2 Study Published in The BMJ: Combination of Cerebral Cytoprotection and Thrombectomy Significantly Reduces Post-Stroke Disability

Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study

MicroPort CardioFlow’s VitaFlow Liberty® TAVI System Receives Market Approval in Morocco, Marking Entry into Africa

China Daily | Simcere eyes growing pharmaceutical niche

Envafolimab Granted FDA Orphan Drug Designation for Gastric and GEJ Cancer

SIM0610, Simcere Zaiming's a Bispecific Antibody-Drug Conjugate Approved for Clinical Trials

Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate

MicroPort® CardioFlow and MicroPort® CRM Complete Strategic Merger: Launching a New Era in Heart Failure Treatment

MicroPort® CardioFlow and MicroPort® CRM Complete Strategic Merger: Launching a New Era in Heart Failure Treatment

Simcere Zaiming Announces Inclusion of Enzeshu® (Suvemcitug for Injection) in China’s 2025 National Medical Insurance Drug List

MicroPort® CardioFlow’s Strategic Merger with MicroPort® CRM Approved by Shareholders, Accelerating the Building of a New Global Pattern for Cardiac Diagnosis and Therapy

MicroPort® CardioFlow’s Strategic Merger with MicroPort® CRM Approved by Shareholders, Accelerating the Building of a New Global Pattern for Cardiac Diagnosis and Therapy

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

SinoMab (03681.HK) Achieves Key Regulatory Milestone as NMPA Accepts IND Applica on for SM17, a Novel IL-25 Receptor An body for Inflammatory Bowel Disease

Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis

Simcere Donates HKD 5 Million to Support Hong Kong Fire Rescue Efforts

MicroPort® CRM launches SmartView Connect™ App Mobile in Europe and Australia, strengthening connected cardiac care for Bluetooth®-enabled devices

Simcere Enters Exclusive Licensing Collaboration with Vigonvita for New Indications of Deuterium Hydrobromide Remididevir Against RSV Infection

MicroPort® EP Launches Pressure-Sensing Pulsed Field Ablation Catheter, Expanding Its Multi-Energy Platform

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

MicroPort® CardioFlow Surpasses 1,000 Overseas TAVI Implantations, Marking Strategic Global Expansion

MicroPort® CardioFlow Surpasses 1,000 Overseas TAVI Implantations, Marking Strategic Global Expansion

Simcere to Start Producing Swiss Insomnia Drug in China, Building Manufacturing Capabilities for Global Supply

Akeso’s Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China

Toumai® Surgical Robot Fluorescence Imaging System DFVision® Receives CE Mark

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

SIM0609 Doses First Patient in Phase I Clinical Study at Peking University Cancer Hospital

GenFleet Announces First-time Inclusion of Fulzerasib into China’s National Reimbursement Drug List

Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025

Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74

Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025

Akeso’s Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China

Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74

Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025

SIM0237 Phase I NMIBC Data Released in an Oral Presentation at SIU2025

First-in-world Phase III Monotherapy Study of an Oral KRAS G12D Inhibitor versus Chemotherapy Initiated in China: GenFleet Therapeutics Announces First Site Initiation of Registrational Study of GFH375, an Oral KRAS (ON/OFF) Inhibitor, for Metastatic Panc

Akeso’s Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

Akeso’s Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer

SinoMab (03681.HK) Wins the 2nd New Quality Productive Forces Enterprises Award

First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025

First Dual-Positive Immunotherapy with PFS and OS Benefit in EGFR+ NSCLC After EGFR-TKI Progression: Ivonescimab Final OS Analysis from HARMONi-A to Be Presented at SITC 2025

CirCode‘s Circular RNA Therapeutic HM2003 Receives FDA Orphan Drug Designation for Thromboangiitis Obliterans

GenFleet Therapeutics Announces First Patient Dosed in a Phase Ib/II Study of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, Combined with Cetuximab or Chemotherapy (AG) for Advanced Solid Tumors including First-line Pancreatic Ductal Adenocarcinoma (PDAC)

GenFleet Announces Promising Efficacy Data of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, among Advanced PDAC Patients in a Late-breaking Oral Presentation at ESMO Congress 2025

HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet

FDA Approved IND Application of Phase 2/3 Clinical Study of JS207 (PD-1/VEGF) for the Neoadjuvant Treatment of NSCLC Patients

Simcere Zaiming and NextCure Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

2024Corporate Social responsibility -Bellen Chemistry Co., Ltd. Yantai

Toumai® Surgical Robot Achieves Global Commercialization Milestone with 100 Orders

MicroPort® Coronary Stents Surpass 10 Million Milestone in Global Shipments and Implantations

BioLink Showcased Smart Single-Use Bioprocessing Solutions at 2025 BPD@Singapore

GenFleet Therapeutics Announces First Patient Dosed with GFH276, a Molecular Glue Pan RAS (ON) Inhibitor, in a Phase I/II Study Treating RAS-mutant Cancer Patients

SIM0609, Simcere Zaiming’s CDH17-targeting ADC is approved by the U.S. FDA to enter clinical trials

Achieving Quality Sleep and improving Daytime Function – Daridorexant Launch Celebrated at the 2025 China Sleep Medicine Development

Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation

Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer

MicroPort® Endovastec™ Completes First Commercial Implantation of Minos™ in Ecuador and Hercules®-LP in Malaysia

GenFleet Therapeutics (2595.HK) Completes Initial Public Offering on HKEX

GenFleet (2595.HK) Completes Initial Public Offering on HKEX

Akeso’s Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)

Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH

Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

Endovastec™’s Cratos™ Completes First Commercial Use in Hungary

SinoMab’s Founder Outlines Its “Biotech 3.0” Roadmap on Blomberg TV The China Show Interview

Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC

Argo Biopharma Completes First Patient Dosing for Phase II Clinical Trial in Chronic Hepatitis B

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

New Sleep Medication Significantly Improves Multiple Sleep Parameters: Phase III Clinical Data of Daridorexant in China Published in SLEEP

New Drug Application (NDA) for Pediatric Influenza Antiviral Innovative Drug Deunoxavir Marboxil

New-generation anti-insomnia drug Daridorexant issues China's first prescription, ushering in a new era of scientific sleep

Argo Biopharma $160M BD Deal with Novartis

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy

New England Journal of Medicine Publishes TARGET-FIRST: 1-Month DAPT with Firehawk™ Stents Lowers Bleeding Without Increasing Ischemic Events

MicroPort CardioFlow's Alwide® Plus Obtains EU CE Mark Approval

MicroPort CardioFlow's Alwide® Plus Obtains EU CE Mark Approval

Akeso's 2025 Interim Results: Commercial Sales Reach New All-Time Highs IO 2.0 + ADC 2.0 Strategy Builds a "Next-Generation" Platform with Global Competitive Edge

Hongene to supply exNA oligonucleotide technology under new licensing deal

Toumai® Robot Enables Three Telesurgeries Across 5,000 km in a Single Day

Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints

First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer

Simcere Zaiming’s Polθ Inhibitor SIM0508 Obtains New IND Approval for Combination Use with Olaparib

MicroPort® CardioFlow’s VitaFlow Liberty® Completes First Commercial Implants in Hungary

MicroPort® CardioFlow’s VitaFlow Liberty® Completes First Commercial Implants in Hungary

SinoMab (03681.HK) and Sun Yat-sen University Institute of Advanced Studies Hong Kong Limited Entered into a Comprehensive Strategic Cooperation Agreement Jointly Building a Global Biomedical Innovation Ecosystem to Accelerate Breakthroughs in Debilitatin

GenFleet Therapeutics Announces Acceptance of Updated Efficacy and Safety Data of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Advanced NSCLC Patients as Late-breaking Abstract for Mini Oral Presentation of IASLC 2025 World Conference on Lung Cancer

MicroPort NeuroScientific Launches NUMEN™ Coil Embolization System in Egypt

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

MicroPort® CardioFlow’s VitaFlow Liberty® Completes First Commercial Implantations in Türkiye

MicroPort® VisionPower’s Cataract Phacoemulsification System Receives Marketing Approval in China

MicroPort® CardioFlow’s VitaFlow Liberty® Completes First Commercial Implantations in Türkiye

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

MicroPort® Endovastec™’s Minos™ Completes First Commercial Implantation in Kazakhstan

Pioneering LNP Expert Dr. Pieter Cullis Joins Hongene’s Scientific Advisory Board

Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

MicroPort EverPace’s IceMagic™ CryoAblation System Receives EU MDR Certification

Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

GFH375 (Oral KRAS G12D Inhibitor) Granted with FDA Fast Track Designation for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

MicroPort® CardioFlow's VitaFlow Liberty® Successfully Completes First Commercial Implantations in Kazakhstan

Novel FGFR2b-targeting ADC is approved by the U.S. FDA to enter clinical trials

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

MicroPort® CardioFlow’s VitaFlow Liberty® Successfully Completes First Commercial Implantations in South Korea

Hongene Supports Clinical Advancement of siRNA DNV001 Using Proprietary Chemoenzymatic Ligation Platform

SinoMab (03681.HK) Globally First-in-Class SM03 (Suciraslimab) Achieves Breakthrough Preclinical Results in SLE,Demonstrating Positive Immune Modulation with Potential Multi-Organ Protection and Superior Long-Term Safety

NDA of Rademikibart, Jointly Developed by Simcere and Connect Biopharma for the Treatment of Atopic Dermatitis Accepted by NMPA

Fulzerasib Granted with Second Approval: First China-developed KRAS G12C Inhibitor Launched in Macau, for Advanced NSCLC Treatment

Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy

MediLink Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of YL217

MediLinks Appoints Dr. Weichang Zhou as Chief Technology Officer

Argo Biopharma Receives IND Approval for Phase II Clinical Trial of Promising siRNA-PEG-IFNα Combination Therapy in Chronic Hepatitis B

Argo Biopharma Announces First Subject Dosed in Phase I Clinical Trial of an Investigational siRNA Therapy BW-40202 Targeting Complement Factor B

MediLink Announces YL201 Granted Breakthrough Therapy Designation by FDA

QUVIVIQ® - The World’s New Generation Anti-Insomnia Drug – Approved for Launch，Significantly Improves Sleep and Daytime Functioning

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis

Simcere Zaiming and NextCure Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025

MicroPort® CardioFlow’s AnchorMan® Marks First Post-Market Use in EU

Argo Biopharma’s Novel siRNA Therapeutic BW-20507 Granted Breakthrough Therapy Designation in China for Chronic Hepatitis B Virus Infection

MicroPort® CardioFlow’s VitaFlow Liberty® Expands Global Presence with Key Milestones in Europe and Latin America

Argo Biopharma Announces Phase 2 Advancement and Milestone Payment for siRNA Molecule BW-00163

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations—Third Approved Indication for Cadonilimab

2025 ASCO ｜ Selected in Rapid Oral Abstract Presentation: Disitamab Vedotin as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer Achieves Efficacy Breakthrough

2025 ASCO | RemeGen Announces Trial Results of c-Met Targeted ADC for Treatment of Non-small Cell Lung Cancer

CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients

RemeGen’s Telitacicept Approved for Treatment of Myasthenia Gravis in China

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

RemeGen’s Novel ADC Drug RC278’s Clinical Trial Application Accepted

Simcere Zaiming Announces Phase 3 Clinical Trial Results for Cetuximab β Injection (Enlituo)

Poised to Reshape Treatment Landscape: A Phase 3 Clinical Trial on Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

RemeGen’s Disitamab Vedotin Gains Approval in China for its Third Indication Making it the First ADC Approved for HER2-Positive Advanced Breast Cancer with Liver Metastasis Globally

Patients’ Visual Acuity Effectively Improved! Results Unveiled for the Phase II Clinical Study on RC28-E in Treating Diabetic Macular Edema | ARVO 2025

Argo Biopharma to Present Promising Phase 1/2a Results of siRNA Therapeutic BW-20507 for Chronic Hepatitis B at EASL Congress 2025 (Late-Breaker)

MicroPort® Showcase Comprehensive CRM and EP Solutions at EHRA 2025

Preclinical Findings of World’s First Clinical-stage Bispecific Antibody for Cachexia Reveal Potent Dual Inhibition of GDF15 and IL-6 Signaling Pathways, and Reversal of Weight Loss & Mitigation of Inflammatory Reactions at Low Effective Dosages: GenFleet

GenFleet Announces Superior Anti-tumor Activity of GFH375/VS-7375, a Highly Selective Oral KRAS G12D (ON/OFF) Inhibitor, in Multiple Preclinical Studies of Monotherapy and Combination Treatments at 2025 AACR Annual Meeting

GenFleet Therapeutics Announces Broad-spectrum Anti-tumor Activity and Low Effective Dosage of GFH276, an Oral Pan RAS (ON) Inhibitor, and its Potential to Overcome Multiple Resistances in Preclinical Findings at Post Presentation of 2025 American Associa

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma

FDA Grants IND Clearance of GFH375/VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Enabling a Phase I/IIa Trial Treating KRAS G12D-mutant Advanced Solid Tumors in the United States

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs. Tislelizumab in Combination with Chemotherapy

Akeso’s Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

MediLink’s YL217 received FDA Clearance of IND Application

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

Akeso’s Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

MicroPort® CardioFlow’s VitaFlow Liberty® Obtains Marketing Approval in India

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

MediLink’s YL217 received FDA Clearance of IND Application

TriApex Launches Its New U.S. Laboratories in Philadelphia

Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe

Junshi Biosciences Announces Toripalimab’s Approval in Australia

JPM 2025 | RemeGen: Maximize Commercial Potential of Pipelines Through Indication Expansion and Therapy Innovation

Argo Biopharma to Present at the J.P. Morgan 43rd Annual Healthcare Conference

CirCode Biomed Just Received First Ever Circular RNA IND Approval from NMPA

MediLink Therapeutics Announces Strategic Partnership with Zai Lab to Develop a Novel LRRC15 Antibody-Drug Conjugate

MicroPort EverPace Introduces Genesis RMN™ Magnetic Navigation Robot to China, Redefining Traditional Ablation Techniques

VitaFlow Liberty® Flex Transcatheter Aortic Valve Implantation System Receives Market Approval from NMPA

MediLink Announces YL201 Granted Orphan-Drug Designation by the US FDA

SinoMab Completed Patient Enrollment in Phase 1b Clinical Trial

Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations

MicroPort®’s Two Products Approved for Fast-Track Registration as Innovative Medical Device in China

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

Biolink Secures Hundreds of Millions RMB New Financing to Fuel Innovations in Bioprocessing “Made in China”

Akeso Secures $250 Million USD to Propel Global Expansion of Its Innovative Drug Pipeline

Junshi Biosciences Announces Ongericimab’s NDA Approval in China

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

Akeso’s Ebronucimab（PCSK9) Approved for Two Indications for the Treatment of Hypercholesterolemia in China

MediLink Therapeutics Wins the 2024 Endpoints 11 Award

HM2002 Injection Completes First Patient Dosing Circular RNA Drug Officially Enters Clinical Trial Stage

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

Qi-biodesign and MGI have reached a strategic cooperation

CirCode Biomed Launches First-in-Human Trial of Circular RNA at Ruijin Hospital

Enrollment Completed in Phase 3 Clinical Study of Disitamab Vedotin Combined with PD-1 Inhibitor as First-Line Treatment for Advanced Urothelial Carcinoma

First Patient In Achieved in the Global Multicenter Phase III Trial on Telitacicept for Myasthenia Gravis 05

Bellen is awarded a Bronze medal from EcoVadis

Argo Biopharma Announces Completion of First Participant Dosing in China Phase I Clinical Study of BW-03, a Novel RNAi Therapeutics for the Treatment of CHB

Qi-biodesign's high oleic acid soybeans have been granted an exemption by the USDA

MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech

MicroPort® CardioFlow Receives Approval for VitaFlow Liberty® in the EU

First Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia

BioLink Formally Announces Its India Office Now Is Fully Functional And Operational

Qi-biodesign and G&P Agritech have signed a strategic cooperation agreement

Qi-biodesign has initiated a strategic partnership with Triumph Haofeng

RemeGen's Telitacicept Granted Fast Track Designation by US FDA for Treatment of Primary Sjögren's Syndrome Following Permission of the Phase 3 Multicenter Global Clinical Trial

Johnson & Johnson Completes Acquisition of Ambrx

iF Design Winner: BioHub® DS Single-Use Desktop Mixing System

CirCode Announces Feasibility Study Agreement to Explore the Potential of Circular RNA Therapeutics

The "Top 10 Scientific Advances of 2023, China" have been announced

BioLink Successfully Completes Series A+ Strategic Financing, Continues to Empower China's Bioprocessing with Innovation

MicroPort EverPace Receives CE MDR Certification for Its Latest Generation Columbus™ 3D EP Navigation System

MicroPort® CardioFlow Receives Approval for Its AnchorMan® LAAC System in China

Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Argo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.

JPM Healthcare Conference 2024|Dr. Fang Jianmin’s Speech: Promote the Global Development of Telitacicept at Full Speed and Create a Pioneer Blockbuster Drug in the Field of B Cell-mediated Autoimmunity

BioLink and Verdot Forge Strategic Partnership to Advance Bioprocessing Technologies in China

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis.

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation ADC in Oncology

MediLink Therapeutics Announces Latest Business Progress with Nona Biosciences

Continuously Ranked | BioLink Named One of China's Top 100 Life Science Service Brands

SinoMab Awarded the "Best Small and Medium-Cap Company” in the “8th Zhitong Caijing Listed Company Awards” Development Potential Recognised by The Capital Market

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

MicroPort® CardioFlow Finishes VitaFlow Liberty® Pre-Market Implantations

Argo Biopharma closed series A+ financing of over 40 milion US dollars led by CS Capital.

Junshi Biosciences Announces FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech

MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech

MicroPort EP Receives FireMagic™ TrueForce™ Ablation Catheter Approval

MediLink Therapeutics is studying YL202 in advanced lung and breast cancer patients.

MediLink Therapeutics is studying YL202 in advanced lung and breast cancer patients.

CirCode Biomed Closes Multi-Million-Dollar Series A Financing

Argo Biopharma’s first siRNA drug approved for clinical study in China, the United States, and Australia.

CirCode Announces Research Agreement with Pfizer to Explore the Potential of Circular RNA Therapeuti

Bellen has successfully obtained a Drug production license

Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer

Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer

Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Commercialize Toripalimab in 21 Countries

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

MicroPort EP FDA Approved for EasyFinder™ Fixed Curve Diagnostic Catheter